<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="79677"><DrugName>filgrastim follow-on biologic, Biosidus</DrugName><DrugNamesKey><Name id="42988984">Biofigran</Name><Name id="42988985">Colstim</Name><Name id="42988986">Granulostim</Name><Name id="42988983">Neutromax</Name><Name id="42754937">filgrastim</Name></DrugNamesKey><DrugSynonyms><Name><Value>filgrastim</Value><Types><Type>USAN</Type><Type>BAN</Type><Type>INN</Type></Types></Name><Name><Value>filgrastim follow-on biologic, Biosidus</Value></Name><Name><Value>Neutromax</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Biofigran</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Colstim</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Granulostim</Value><Types><Type>Trade Name</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1032377">Biosidus SA</CompanyOriginator><CompaniesPrimary><Company id="20452">UCB SA</Company><Company id="1032377">Biosidus SA</Company><Company id="29062">Zydus-Cadila Group</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1032377" type="Company"><TargetEntity id="4297528552" type="organizationId">Biosidus SA</TargetEntity></SourceEntity><SourceEntity id="20452" type="Company"><TargetEntity id="4295859381" type="organizationId">Ucb SA</TargetEntity></SourceEntity><SourceEntity id="29062" type="Company"><TargetEntity id="4296112573" type="organizationId">Zydus Cadila Group</TargetEntity></SourceEntity><SourceEntity id="1991" type="ciIndication"><TargetEntity id="D70" type="ICD10"></TargetEntity><TargetEntity id="10029354" type="MEDDRA"></TargetEntity><TargetEntity id="D009503" type="MeSH"></TargetEntity><TargetEntity id="-506284464" type="omicsDisease"></TargetEntity><TargetEntity id="1002" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3151" type="Action"><TargetEntity id="1121" type="Mechanism">G-CSF Mimetics</TargetEntity><TargetEntity id="3384" type="Mechanism">G-CSF Receptor Agonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00800" type="ciTarget"><TargetEntity id="36485060414413" type="siTarget">Granulocyte colony-stimulating factor receptor</TargetEntity><TargetEntity id="276" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Neutropenia - Argentina - Jun-2012</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="1991">Neutropenia</Indication><Indication id="651">Cancer</Indication></IndicationsPrimary><ActionsPrimary><Action id="3151">GCSF receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="961">Follow on biological product</Technology><Technology id="85">Protein recombinant</Technology><Technology id="740">Infusion</Technology></Technologies><LastModificationDate>2017-05-29T06:44:56.000Z</LastModificationDate><ChangeDateLast>2016-06-15T00:00:00.000Z</ChangeDateLast><AddedDate>2012-07-30T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="1032377"&gt;Biosidus&lt;/ulink&gt; has developed and launched a follow-on biologic version of &lt;ulink linkType="Drug" linkID="3130"&gt;filgrastim&lt;/ulink&gt;, (Neutromax; Biofigran; Colstim; Granulostim), a recombinant methionyl, non-glycosylated form of granulocyte colony-stimulating factor (GM-CSF), available as a ready for injection solution, for the treatment of neutropenia [&lt;ulink linkType="Reference" linkID="1306599"&gt;1306599&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1306601"&gt;1306601&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1449626"&gt;1449626&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2006, the product was approved in China for Biosidus; by August 2012, it had been launched there by &lt;ulink linkType="Company" linkID="20452"&gt;UCB&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1317452"&gt;1317452&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1317454"&gt;1317454&lt;/ulink&gt;]. By December 2010, Indian marketing licensee &lt;ulink linkType="Company" linkID="29062"&gt;Zydus-Cadila&lt;/ulink&gt; had received marketing authorization for the drug [&lt;ulink linkType="Reference" linkID="1137321"&gt;1137321&lt;/ulink&gt;]; in July 2012, this was still the case [&lt;ulink linkType="Reference" linkID="1312013"&gt;1312013&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1032377">Biosidus SA</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-08-23T00:00:00.000Z</StatusDate><Source id="1317454" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20452">UCB SA</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-08-23T00:00:00.000Z</StatusDate><Source id="1317454" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032377">Biosidus SA</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-06-21T00:00:00.000Z</StatusDate><Source id="1306599" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29062">Zydus-Cadila Group</Company><Country id="IN">India</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-12-31T00:00:00.000Z</StatusDate><Source id="1312442" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1032377">Biosidus SA</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-05-17T00:00:00.000Z</StatusDate><Source id="1317452" type="OTHER"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00800"><Name>GCSF receptor</Name><SwissprotNumbers><Swissprot>P40223</Swissprot><Swissprot>Q99062</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1306599" linkType="reference" linkID="1306599"&gt;1306599&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1032377">Biosidus SA</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20452">UCB SA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="29062">Zydus-Cadila Group</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><Deals><Deal id="141380" title="UCB to market Bio Sidus' follow-on biologic Granulostim"></Deal><Deal id="141386" title="Zydus Cadila to market Bio Sidus' EPO in India and G-CSF"></Deal></Deals><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>